ProShare Advisors LLC Has $1.40 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

ProShare Advisors LLC grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 61.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,801 shares of the company's stock after purchasing an additional 21,939 shares during the quarter. ProShare Advisors LLC's holdings in Hims & Hers Health were worth $1,398,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Crewe Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. lifted its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Hims & Hers Health during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HIMS shares. Needham & Company LLC restated a "buy" rating and issued a $61.00 price target on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price objective for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Stock Down 5.4%

Shares of Hims & Hers Health stock opened at $57.91 on Thursday. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company has a market capitalization of $12.96 billion, a price-to-earnings ratio of 131.61 and a beta of 1.84. The firm's 50-day moving average price is $37.10 and its two-hundred day moving average price is $34.54.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.05 EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In related news, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the completion of the transaction, the chief executive officer now directly owns 173,655 shares in the company, valued at $5,900,796.90. This represents a 42.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the transaction, the insider now directly owns 193,601 shares of the company's stock, valued at approximately $9,319,952.14. The trade was a 8.20% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 618,936 shares of company stock worth $25,182,692. Insiders own 13.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.